Lineage Cell Therapeutics (NYSEAMERICAN:LCTX – Free Report) had its price objective reduced by B. Riley from $4.00 to $3.00 in a research note released on Friday,Benzinga reports. They currently have ...

There's more to work than life.

Q4 2024 Management View Greg Lehmkuhl, CEO, highlighted the company's accomplishments, including executing the largest REIT IPO of all time in 2024, reducing leverage below 5x, and achieving ...

Lineage, Inc. (NASDAQ:LINE – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the eighteen ...

Scotiabank analyst Greg McGinniss raised the firm’s price target on Lineage (LINE) to $74 from $73 and keeps an Outperform rating on the shares. While 2025 is expected to experience more ...

Q4 2024 Earnings Call Transcript March 10, 2025 Lineage Cell Therapeutics, Inc. beats earnings expectations. Reported EPS is ...

AGI 1.0 Demo follows the “Data Recognize Its Lineage” approach, combining ontology and dynamic micro-tuning, zero cost but ...

For the year, the company reported funds from operations of $705 million. Revenue was reported as $5.34 billion. Lineage expects full-year funds from operations in the range of $3.40 to $3.60 per ...

Lineage Inc. investors seeking returns from last year’s biggest initial public offering are anxiously awaiting its earnings report Wednesday. Shares of the cold-storage real estate investment ...

--(BUSINESS WIRE)--Lineage, Inc. (NASDAQ ... sheet and financial outlook provides the capacity to deploy more than $1.5 billion of capital in 2025. We are poised to execute on our robust ...